Clinical trials: Bladder Cancers
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy
RATIONALE: Drugs used in chemotherapy such as irinotecan use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00066612
- Testing
- irinotecan hydrochloride
- Volunteers
- 45 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer
Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer
The main objective of this study is to compare the effectiveness of Leukine \& Neupogen to decrease the incidence of grade 3 \& 4 neutropenia in the treatment of patients receiving cisplatin \& gemcitabine for urothelial…
- Trial name
- NCT00237575
- Testing
- gemcitabine, cisplatin, sargramostim
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Kentucky
Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
177Lu-FAP-2286 Treatment in Urethelial Neoplasms: Utility and Safety as a Novel Treatment.
Ga-68-FAPI has recently been proven to be superior to F-18-FDG in various cancers. These results have also raised hope in using FAP radiopharmaceuticals with theranostic approach.
- Trial name
- FAUNUS (NCT06880757)
- Testing
- Radionuclide treatment with Lu-177 FAPI
- Volunteers
- 10 people
- Sponsor
- Ankara University
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Bladder Cancer TNM Staging Primary Tumor (T) Ta, Bladder Cancer TNM Staging Primary Tumor (T) T1
Intravesical Adjuvant Electromotive Mitomycin-C
In laboratory and clinical studies, intravesical electromotive drug administration increased mitomycin bladder uptake, improving clinical efficacy in high-risk non-muscle invasive urothelial bladder cancer.
- Conditions
- Bladder Cancer TNM Staging Primary Tumor (T) Ta, Bladder Cancer TNM Staging Primary Tumor (T) T1, Bladder Cancer Transitional Cell Grade
- Trial name
- EMDA/MMC (NCT01920269)
- Testing
- Trans-urethral resection, intravesical passive diffusion mitomycin, intravesical electromotive mitomycin
- Where
- Italy
- Volunteers
- 331 people
- Sponsor
- University of Rome Tor Vergata
Solid Tumors
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult participants with relapsed/refractory solid tumors…
- Trial name
- NCT03634982
- Testing
- RMC-4630
- Where
- 12 sites in United States
- Volunteers
- 133 people
- Sponsor
- Revolution Medicines, Inc.
Genito Urinary Cancer, Bladder Cancer
Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers
The objective of this study is to obtain human blood CD34+ hematopoietic stem/progenitor cells (HSPCs) to reconstitute a match human immune system in our PDX model.
- Conditions
- Genito Urinary Cancer, Bladder Cancer, Kidney Cancer, Prostate Cancer
- Trial name
- Immune PDX (NCT03134027)
- Testing
- Bone marrow biopsy, Tumor biopsy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
Bladder Cancer
Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)
This study is a two-arm phase II randomized trial investigating patients with luminal subtype muscle-invasive bladder cancer (MIBC) receiving neoadjuvant therapy (NAT) followed by cystectomy compared to those receiving upfront…
- Trial name
- NCT07762586
- Testing
- Neoadjuvant Therapy, Upfront radical cystectomy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Rutgers, The State University of New Jersey
Locally Advanced Bladder Urothelial Carcinoma, Metastatic Transitional Cell Carcinoma
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
This pilot phase II trial studies how well sapanisertib works in treating patients with bladder cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body…
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Metastatic Transitional Cell Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Carcinoma
- Trial name
- NCT03047213
- Testing
- Sapanisertib
- Where
- 20 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Hematuria - Cause Not Known
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
This study includes adult patients who see a urologist because of blood in their urine. The amount is so small it can only be seen with a microscope. This is called microhematuria. There can be many reasons for microhematuria.
- Trial name
- CREDIBLE (NCT06394869)
- Testing
- Cxbladder Triage Plus
- Where
- 20 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Pacific Edge Limited
Bladder Cancer
Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002919
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urinary Bladder Neoplasms
Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC
The purpose of the study is to investigate the safety, tolerability, and preliminary efficacy of the monoclonal bispecific trifunctional antibody Catumaxomab in patients with non-muscle invasive bladder cancer (NMIBC).
- Trial name
- NCT04819399
- Testing
- Catumaxomab
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Lindis Biotech GmbH
Cystoscopic Surgical Procedures, Pain
Physicians' Perception About Patient Pain in Flexible Cystoscopy With Local Anesthesia
Cystoscopy with local anesthesia is commonly performed for the follow-up of bladder cancer, evaluation of hematuria, assessment of urethral strictures, and examination of the lower urinary tract.
- Trial name
- NCT06944314
- Testing
- Diagnostic procedures, Flexible Cystoscopy
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Marmara University
Bladder Cancer Patients Candidate for Radical Cystectomy
Preoperative Subclinical DVT Screening in Locally Advanced Bladder Cancer Patients Candidate for Radical Cystectomy.
Preoperative subclinical DVT screening in locally advanced bladder cancer patients candidate for radical cystectomy.
- Trial name
- NCT04502498
- Testing
- Lower limb duplex & doppler
- Volunteers
- 60 people
- Sponsor
- Kasr El Aini Hospital
NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma
A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.
This study is being conducted to establish a novel tumor tissue- and blood-based biomarker test to assess early systemic and local response to immunomodulation by BCG immunotherapy in patients with high-risk non-muscle invasive…
- Conditions
- NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma, Bladder (Urothelial, Transitional Cell) Cancer, Urothelial Carcinoma Bladder
- Trial name
- BCG-TIME (NCT07064863)
- Testing
- Gemcitabine + BCG, BCG (TICE strain)
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Queen's University
Urothelial Carcinoma
The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence
The investigators evaluated the efficacy of a single early intravesical instillation of doxetaxel in the prevention of bladder recurrence after nephroureterectomy or distal ureterectomy for upper urinary tract urothelial…
- Trial name
- NCT03209206
- Testing
- Docetaxel
- Where
- South Korea
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Over-Active Bladder
VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate
The purpose of this study is to determine if Vesicare (Solifenacin succinate) is effective in treating over-active bladder symptoms during radiation therapy of the prostate.
- Trial name
- NCT01777217
- Testing
- Solifenacin succinate
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Advanced Research Network
Urothelial Carcinoma, Bladder Cancer
Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic
Our multicenter observational study is a non-profit prospective study. The study was born from the Amplitude Project, which comprise the SOD of Minimally Invasive Robotic Urological Surgery and Renal Transplants of AOU Careggi…
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Urothelial Neoplasm, Urothelial Carcinoma Bladder
- Trial name
- NCT04770974
- Testing
- Biomarkers and proteomics
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- University of Florence
Cancer, Neoadjuvant Therapy
Development and Validation of a Multimodal Fusion Artificial Intelligence Model for Predicting the Efficacy of Neoadjuvant Treatment of Bladder Cancer
This study is a multi-center observational study without interventions, including the construction of an AI predictive model, with retrospective and prospective testing.
- Trial name
- NCT06909643
- Testing
- Artificial intelligence (AI)-based predictive model
- Where
- China
- Volunteers
- 469 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Bladder Cancer
Multimodal Rehabilitation Program to Bladder Cancer Patients
The incidence of bladder cancer is increasing. Denmark have approximately 1800 incidence per year. The disease is most frequently in males above the age of 70 years.
- Trial name
- MRPBC (NCT01329107)
- Testing
- Multimodal Intervention
- Where
- 2 sites in Denmark
- Volunteers
- 129 people
- Sponsor
- University of Aarhus
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.